Clinical Scorecard: Exploratory Trial of Topical Imiquimod in Conjunction with Pembrolizumab for Patients with Unresectable Cutaneous Metastatic Melanoma

At a Glance

Key Highlights

• Objective response rate (ORR) of 57.1% with 42.9% achieving complete response.
• Median treatment exposure was 8 cycles.
• 7-month progression-free survival (PFS) rate was 57.1%.
• Toxicities were mostly grade 1, with fatigue and anemia being the most common.
• Combination therapy demonstrated promising antitumor activity.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of cutaneous metastatic melanoma based on clinical evaluation and imaging.

Management

• Combination of topical imiquimod with pembrolizumab for unresectable cutaneous metastases.

Monitoring & Follow-up

• Monitor for objective response rate and progression-free survival.

Risks

• Potential for grade 1 toxicities, primarily fatigue and anemia.

Patient & Prescribing Data

Seven patients enrolled, predominantly male and non-Hispanic White.

Topical imiquimod applied Monday–Friday each cycle alongside pembrolizumab IV every 21 days.

Clinical Best Practices

• Consider local immune modulation strategies in conjunction with systemic therapies for cutaneous melanoma.
• Evaluate patient response using RECIST v1.1 criteria.

Related Resources & Content

• Clinical Trial NCT03276832